Avina K. Singh

Avina K. Singh

Hematology | Oncology
675 E Nicollet Blvd Ste 200
Burnsville, MN 55337

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

Journal: The New England journal of medicine
Published: July 15, 2026

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Journal: The New England journal of medicine
Published: October 16, 2024

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.

Journal: Blood advances
Published: April 23, 2024

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Journal: Blood
Published: November 29, 2021

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

Journal: Blood
Published: December 30, 2020

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Journal: The Lancet. Oncology
Published: May 13, 2020

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: August 01, 2019
Showing 1-7 of 7

Last Updated: 09/26/2026